Sex difference in induction of hepatic CYP2B and CYP3A subfamily enzymes by nicardipine and nifedipine in rats

Toxicology and Applied Pharmacology

Volumn 196, Issue 1, 2004, Pages 20-28

  Konno, Yoshihiro ^a   Sekimoto, Masashi ^a   Nemoto, Kiyomitsu ^a   Degawa, Masakuni ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

CYP2B; CYP3A; Cytochrome P450; Induction; Nicardipine; Nifedipine; Rat liver

Indexed keywords

CYTOCHROME P450 2B; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; MESSENGER RNA; NICARDIPINE; NIFEDIPINE; PENTOXYRESORUFIN DEALKYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEALKYLATION; DRUG MECHANISM; EXPERIMENTAL RAT; FEMALE; GENE ACTIVATION; LIVER MICROSOME; MALE; MEASUREMENT; NONHUMAN; OXIDATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; WESTERN BLOTTING;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; ISOENZYMES; MALE; MICROSOMES, LIVER; NICARDIPINE; NIFEDIPINE; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX FACTORS; STEROID HYDROXYLASES;

EID: 1642301013     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.12.009     Document Type: Article

References (31)

1. Agrawal A.K., Shapiro B.H. Phenobarbital induction of hepatic CYP2B1 and CYP2B2: pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose. Mol. Pharmacol. 49:1996;523-531.
2. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
3. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
4. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 48:1994;923-936.
5. Campana C., Regazzi M.B., Buggia I., Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin. Pharmacokinet. 30:1996;141-179.
6. Cooper K.O., Reik L.M., Jayyosi Z., Bandiera S., Kelly M., Ryan D., Daniel R., McCluskey S.A., Levin W., Thomas P.E. Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch. Biochem. Biophys. 301:1993;345-354.
7. Degawa M., Tanimura S., Agatsuma T., Hashimoto Y. Hepatocarcinogenic heterocyclic aromatic amines that induce cytochrome P-448 isozymes, mainly cytochrome P-448H (P450 1A2), responsible for mutagenic activation of the carcinogens in rat liver. Carcinogenesis. 10:1989;1119-1122.
8. Drocourt L., Pascussi J.-M., Assenat E., Fabre J.-M., Maurel P., Vilarem M.-J. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 29:2001;1325-1331.
9. Gonzalez F.J., Song B.-J., Hardwick J.P. Pregnenolone 16α-carbonitrile-inducible P450 gene family: gene conversion and differential regulation. Mol. Cell. Biol. 6:1986;2969-2976.
10. Kasahara T., Hashiba M., Harada T., Degawa M. Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis. 23:2002;491-498.
11. Koleva M.R., Stoychev T.S. On the enzyme-inducing action of calcium antagonists. Arch. Toxicol. 67:1993;294-296.
12. Koleva M.R., Stoychev T.S. Effect of nifedipine, verapamil and diltiazem on the enzyme-inducing activity of phenobarbital and beta-naphthoflavone. Gen. Pharmacol. 26:1995;225-228.
13. Konno Y., Nemoto K., Degawa M. Induction of hepatic cytochrome P450s responsible for the metabolism of xenobiotics by nicardipine and other calcium channel antagonists in the male rat. Xenobiotica. 33:2003;119-129.
14. Larsen M.C., Brake P.B., Parmar D., Jefcoate C.R. The induction of five rat hepatic P450 cytochromes by phenobarbital and similarly acting compounds is regulated by a sexually dimorphic, dietary-dependent endocrine factor that is highly strain specific. Arch. Biochem. Biophys. 315:1994;24-34.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
16. Ma B., Prueksaritanont T., Lin J.H. Drug interaction with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 28:2000;125-130.
17. Maenpaa J., Ruskoaho H., Pelkonen O. Inhibition of hepatic microsomal drug metabolism in rats by five calcium antagonists. Pharmacol. Toxicol. 64:1989;446-450.
18. Mahnke A., Strotkamp D., Roos P.H., Hanstein W.G., Chabot G.G., Nef P. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch. Biochem. Biophys. 337:1997;62-68.
19. Murray M., Butler A.M. Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J. Pharmacol. Exp. Ther. 279:1996;1447-1452.
20. Nemoto K., Miyata S., Nemoto F., Yasumoto T., Murai U., Kageyama H., Degawa M. Gene expression of neurotrophins and their receptors in lead nitrate-induced rat liver hyperplasia. Biochem. Biophys. Res. Commun. 275:2000;472-476.
21. Oinonen T., Lindros K.O. Hormonal regulation of the zonated expression of cytochrome P450 3A in rat liver. Biochem. J. 309:1995;55-61.
22. Omiecinski C.J., Hassett C., Costa P. Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1. Mol. Pharmacol. 38:1990;462-470.
23. Pichard L., Fabre I., Fabre G., Domergue J., Saint A.B., Mourad G., Maurel P. Cyclosporin A drug Interactions. Screening for inducers and inhibitor of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:1990;595-606.
24. Robertson G.R., Farrell G.C., Liddle C. Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem. Biophys. Res. Commun. 242:1998;57-60.
25. Rosenthal T., Ezra D. Calcium antagonists: drug interactions of clinical significance. Drug Saf. 13:1995;157-187.
26. Schlanz K.D., Myre S.A., Bottorff M.B. Pharmacokinetic interactions with calcium channel antagonists. Clin. Pharmacokinet. 21:1991;344-356.
27. Shapiro B.H., Pampori N.A., Lapenson D.P., Waxman D.J. Growth hormone-dependent and -independent sexually dimorphic regulation of phenobarbital-induced hepatic cytochromes P450 2B1 and 2B2. Arch. Biochem. Biophys. 312:1994;234-239.
28. Wang H., Strobel H.W. Regulation of CYP3A9 gene expression by estrogen and catalytic studies using cytochrome P450 3A9 expressed in Escherichia coli. Arch. Biochem. Biophys. 344:1997;365-372.
29. Willson T.M., Kliewer S.A. PXR, CAR and drug metabolism. Nat. Rev. 1:2002;259-266.
30. Xie W., Barwick J.L., Downes M., Blumberg B., Simon C.M., Nelson M.C., Neuschwander-tetris B.A., Brunt E.M., Guzelian P.S., Evans R.M. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 406:2000;435-439.
31. Zangar R.C., Okita J.R., Kim H., Thomas P.E., Anderson A., Edwards R.J., Springer D.L., Okita R.T. Effect of calcium channel antagonists nifedipine and nicardipine on rat cytochrome P450 2B and 3A forms. J. Pharmacol. Exp. Ther. 290:1999;1436-1441.